| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
FDA Commissioner Stephen Hahn said Monday that, by the end of the week, U.S. labs would have enough materials to perform close to 1 million tests. Public health experts say that figure is misleading because it is far larger than the number of samples that can be processed in labs in the coming weeks.[CR-LF][CR-LF]The realistic estimate is now likely around 5,000 each day, according to a public health lab industry group.
With legal marijuana use laws continuing to make traction throughout the U.S., and the perception of a dwindling job applicant pool, some employers are asking if they should continue to conduct screening for marijuana. Some employers are also challenging the entire idea of performing drug testing in their workplaces. Is there still a benefit to having a drug-free workplace program?
It could be weeks before the United States can meet the demand for coronavirus testing because doctors, hospitals and some public health labs say they aren’t set up yet to do the tests.[CR-LF][CR-LF]Ratcheting up the country’s ability to detect the disease is crucial to understand how the coronavirus — now confirmed in at least 12 states — is spreading. But testing so far has been severely limited by problems with a diagnostic test developed by CDC.
Aimed at making it a bit easier to track the ever-increasing list of coronavirus plays, here is a representative listof diagnostic companies that have either experienced recent volatility or may announce plans to develop tests for COVID-19. Some companies, of course, are more credible players than others.
Primary care physicians may be overconfident in their ability to recognize prescription drug misuse, a researcher suggested here.[CR-LF][CR-LF]An analysis that juxtaposed survey data from 500 primary care physicians with over a half million drug test results showed that nearly three-quarters of doctors trusted their patients to take medications as prescribed, but half of specimens showed signs of misuse, reported Jeffrey Gudin, MD, of Rutgers New Jersey Medical School in Newark, at the American Academy of Pain Medicine annual meeting.